Objectives: This study aims to evaluate the effectiveness of preemptive administration of non-steroidal anti-inflammatory Piroxicam-beta-Cyclodextrin on risk and level of tooth sensitivity caused by in-office bleaching procedures using 35% hydrogen peroxide.
Fifty patients will be selected for this triple-blind, randomized, cross-over, placebo-controlled clinical trial. Piroxicam-beta-Cyclodextrin (200 mg) or placebo will be administrated in a single-dose thirty minutes prior to bleaching procedure. The whitening treatment with 35% hydrogen peroxide will be carried out in two sessions with a 7-day interval. Tooth sensitivity will be assessed Immediately before bleaching agent removal and up to 24 hours after each session the procedure using analog visual and verbal scales. Color alteration will be assessed by a bleach guide scale 7 days after each session. Relative risk to sensitivity will be calculated and adjusted by session; while comparison of overall risk will performed by Fisher's exact test. Data on the sensitivity level for both scales and color shade will be subjected to the Mann-Whitney and Friedman tests, respectively (α = 0.05).

Start Date13 Dec 2016

Sponsor / Collaborator

Fundação Universidade Federal de Sergipe

100 Clinical Results associated with Piroxicam betadex

100 Translational Medicine associated with Piroxicam betadex

100 Patents (Medical) associated with Piroxicam betadex

Literatures (Medical) associated with Piroxicam betadex

24 Apr 2020·Recent Patents on NanotechnologyQ4 · MATERIALS SCIENCE

A Comprehensive Patent Review on β-cyclodextrin Cross-linked Nanosponges for Multiple Applications

Q4 · MATERIALS SCIENCE

Article

Author: Shende, Pravin ; Pawar, Sandip

Background: :Currently, the most important challenge in the development of therapeutics and actives is their poor aqueous solubility and bioavailability.Objective: :The low aqueous solubility, poor pharmacokinetic properties, and bioavailability associated with novel actives manifest in numerous challenges in the formulation of conventional dosage forms like tablets, capsules, suspensions, emulsions, etc. Nanosponges are a novel class of drug delivery system capable of encapsulating or entrapping both lipophilic and hydrophilic drugs. Target-specific drug delivery and controlled drug release are the advantages offered by nanosponges which make them a promising anti-tumor drug delivery system.Methods:Nanosponges are colloidal structures comprising solid nanoparticles with cavities and meshlike structures for encapsulation of wide varieties of substances like antineoplastic agents, proteins and peptides, volatile oils, genetic material, etc. The methods of preparation of β-cyclodextrin-based nanosponges include solvent evaporation method, emulsion solvent evaporation method, ultrasound-assisted synthesis, hyper cross-linked cyclodextrin and interfacial phenomenon method. A large variety of nanosponges- based formulations are available in the market and some formulations of prostavastin, brexin, glymesason, mena-gargle, etc. are under clinical trials.Results: :Nanosponges possess potential applications in target site-specific drug delivery to liver, spleen, and lungs. Due to the surface functionalization, nanosponges show broad applications in water purification, protein delivery, chemical sensors, detection of explosives, agriculture, etc. In the near future, nanosponges-based products will capture a huge market for commercialization due to their improved properties and advantages.Conclusion: :This review provides an account of the patents related to nanosponges (2006-2018) and covers the broad applications of β-cyclodextrin-based nanosponges, their roles in vaccine delivery, cancer therapy, fire engineering, water purification, etc.

01 Aug 2010·Brazilian Journal of Medical and Biological ResearchQ4 · MEDICINE

Evaluation of piroxicam-β-cyclodextrin as a preemptive analgesic in functional endoscopic sinus surgery

Q4 · MEDICINE

ArticleOA

Author: Topçu, I. ; Ekici, Z. ; Keleş, G.T. ; Yentür, A.

The preemptive analgesic efficacy and adverse effects of preoperatively administered piroxicam-beta-cyclodextrin for post-endoscopic sinus surgery pain was determined in a prospective, double-blind, randomized, clinical study. Seventy-five American Society of Anesthesiologists status I-II patients, aged 18-65 years, were divided into three groups with similar demographic characteristics: group 1 received 20 mg piroxicam-beta-cyclodextrin, group 2 received 40 mg piroxicam-beta-cyclodextrin and group 3 received placebo orally before induction of general anesthesia. A blinded observer recorded the incidence and severity of pain at admission to the post-anesthesia care unit (PACU), at 15, 30, and 45 min in the PACU, and 1, 2, 4, 6, and 24 h postoperatively. All patients received patient-controlled morphine analgesia during the postoperative period and consumption was recorded for 24 h. During the PACU period, mean visual analogue scale values were significantly lower in groups 1 and 2 compared to group 3 (P < 0.05). During the postoperative period, morphine consumption was 3.03 +/- 2.54, 2.7 +/- 2.8, and 5.56 +/- 3.12 mg for each group, respectively (P < 0.05). As a side effect, bleeding was observed in groups 1 and 3, nausea and vomiting in all groups, and edema only in group 3. However, no significant differences were detected in any of the parameters analyzed, which also included epigastric pain, constipation/diarrhea and headache. Similar hematological test results were obtained for all groups. Preemptive administration of piroxicam-beta-cyclodextrin effectively reduced analgesic consumption, and 40 mg of the drug was more effective than 20 mg piroxicam-beta-cyclodextrin without side effects during the postoperative period.

01 Oct 2008·Journal of Clinical Pharmacy and TherapeuticsQ4 · MEDICINE

Effects of piroxicam-beta-cyclodextrin sachets on abnormal postural sway in patients with chronic low back pain

Q4 · MEDICINE

Article

Author: K.‐C. Tsai ; L.‐C. Chen ; C.‐C. Chang ; S.‐T. Chang ; H.‐Y. Chu

BACKGROUNDThe clinical effects of piroxicam-beta-cyclodextrin (PBC) in sachet form have been surveyed in patients with osteoarthritic or acute pain in western countries, but scarcely studied in those with chronic low back pain (LBP), and never investigated in the field of postural sway. The aim of this study was to evaluate the clinical effects of PBC in sachet form prescribed in patients with chronic backache in local Asian when compared with those of plain piroxicam.METHODSAfter randomized allocation and experimental exclusion, a total of 42 eligible patients were randomized into two groups, the sachet group (n = 23) and the piroxicam tablet group (n = 19). Both groups were administered the same dosage, orally per day (daily dose = 20 mg). The duration of trial was 28 days. Efficacy was assessed with pain score, disability index and postural sway.RESULTSThe patients in sachet group showed greater improvement in pain score and disability index than those who took piroxicam tablets. There were significantly lower sway velocity and intensity at almost all different conditions than baseline profiles in both groups (P < 0.05). However, there was no significant difference of sway velocity and intensity in the piroxicam tablets group with regard to eyes open or eyes closed in 20 degrees dorsiflexion.CONCLUSIONSPiroxicam-beta-cyclodextrin (PBC) sachet may have greater improvement in the treatment of chronic LBP and possess the extended effects on postural abnormality relevant to chronic LBP.

100 Deals associated with Piroxicam betadex

External Link

KEGG	Wiki	ATC	Drug Bank
D05511	Piroxicam betadex	M02AA07 M01AC01 S01BC06	DB00554

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ankylosing Spondylitis	ES	-	25 Feb 1999
Osteoarthritis	ES	-	25 Feb 1999
Musculoskeletal Diseases	DE	-	17 Feb 1999
Rheumatic Diseases	BR	-	15 Feb 1999
Arthritis	IT	-	26 Jul 1987
Inflammation	GR	CHIESI Farmaceutici SpA	-
Inflammation	CZ	CHIESI Farmaceutici SpA	-
Inflammation	EG	CHIESI Farmaceutici SpA	-
Pain	CZ	CHIESI Farmaceutici SpA	-
Pain	EG	CHIESI Farmaceutici SpA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Piroxicam betadex

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation